BACKGROUND: Different practices for the treatment of prostate cancer patients exist in Germany. OBJECTIVES: The aim of this analysis was to investigate current practice for the treatment of patients with prostate cancer in urological IQUO partner practices (Interest Group for Quality Assurance in the Work of Office-based Uro-oncologists in Germany) dependent on tumor stage and risk factors. The analysis focused on T1/T2 and T3/T4 patients. In addition, applied therapies were analyzed based on risk group classification (CAPRIS, cancer of the prostate identification screening). MATERIALS AND METHODS: This retrospective cross-sectional analysis includes 1000 patients with prostate cancer with at least 12 months of documentation from the OnkoDataMed (ODM) database between February 2008 and May 2012. The 122 IQUO medical practices included were randomly selected; maximally 50 patients per practice were included in the analysis. The database was analyzed in terms of localized T1/T2 tumors and advanced T3/T4 tumors. Risk groups were formed according to parameters of the initial diagnosis including PSA value, tumor stage, and Gleason score. Descriptive statistics were performed to analyze all parameters. RESULTS AND CONCLUSIONS: As expected, PSA is the critical parameter for follow-up and therapy monitoring. Newer therapeutic options have only been initiated to a limited extent. Differentiated risk assessment has not been sufficiently used; however, it does provide a good opportunity for more individualized therapy in the future.
BACKGROUND: Different practices for the treatment of prostate cancerpatients exist in Germany. OBJECTIVES: The aim of this analysis was to investigate current practice for the treatment of patients with prostate cancer in urological IQUO partner practices (Interest Group for Quality Assurance in the Work of Office-based Uro-oncologists in Germany) dependent on tumor stage and risk factors. The analysis focused on T1/T2 and T3/T4 patients. In addition, applied therapies were analyzed based on risk group classification (CAPRIS, cancer of the prostate identification screening). MATERIALS AND METHODS: This retrospective cross-sectional analysis includes 1000 patients with prostate cancer with at least 12 months of documentation from the OnkoDataMed (ODM) database between February 2008 and May 2012. The 122 IQUO medical practices included were randomly selected; maximally 50 patients per practice were included in the analysis. The database was analyzed in terms of localized T1/T2 tumors and advanced T3/T4 tumors. Risk groups were formed according to parameters of the initial diagnosis including PSA value, tumor stage, and Gleason score. Descriptive statistics were performed to analyze all parameters. RESULTS AND CONCLUSIONS: As expected, PSA is the critical parameter for follow-up and therapy monitoring. Newer therapeutic options have only been initiated to a limited extent. Differentiated risk assessment has not been sufficiently used; however, it does provide a good opportunity for more individualized therapy in the future.
Authors: G Adler; T Seufferlein; S C Bischoff; H-J Brambs; S Feuerbach; G Grabenbauer; S Hahn; V Heinemann; W Hohenberger; J M Langrehr; M P Lutz; O Micke; H Neuhaus; P Neuhaus; H Oettle; P M Schlag; R Schmid; W Schmiegel; K Schlottmann; J Werner; B Wiedenmann; I Kopp Journal: Z Gastroenterol Date: 2007-06 Impact factor: 2.000
Authors: Axel Heidenreich; Patrick J Bastian; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Theodor van der Kwast; Malcolm Mason; Vsevolod Matveev; Thomas Wiegel; F Zattoni; Nicolas Mottet Journal: Eur Urol Date: 2013-10-06 Impact factor: 20.096
Authors: Frances A Shepherd; José Rodrigues Pereira; Tudor Ciuleanu; Eng Huat Tan; Vera Hirsh; Sumitra Thongprasert; Daniel Campos; Savitree Maoleekoonpiroj; Michael Smylie; Renato Martins; Maximiliano van Kooten; Mircea Dediu; Brian Findlay; Dongsheng Tu; Dianne Johnston; Andrea Bezjak; Gary Clark; Pedro Santabárbara; Lesley Seymour Journal: N Engl J Med Date: 2005-07-14 Impact factor: 91.245
Authors: N Breslow; C W Chan; G Dhom; R A Drury; L M Franks; B Gellei; Y S Lee; S Lundberg; B Sparke; N H Sternby; H Tulinius Journal: Int J Cancer Date: 1977-11-15 Impact factor: 7.396
Authors: Anthony V D'Amico; Judd Moul; Peter R Carroll; Leon Sun; Deborah Lubeck; Ming-Hui Chen Journal: J Clin Oncol Date: 2003-06-01 Impact factor: 44.544
Authors: Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman Journal: N Engl J Med Date: 2004-05-27 Impact factor: 91.245
Authors: Marie C Hupe; Peter Hammerer; Miriam Ketz; Nils Kossack; Christiane Colling; Axel S Merseburger Journal: Front Oncol Date: 2018-11-27 Impact factor: 6.244